Axitinib

Licensed by Pfizer Catalog No.S1005 Synonyms: AG 013736

Axitinib Chemical Structure

Molecular Weight(MW): 386.47

Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Representative confocal image (10 x objective) of individual spheroids fixed, sectioned, and then stained for vimentin (green) and DNA (DAPI, blue). Vimentin protein expression from sections quantitated from multiple replicate spheroid treatments with U0126 and axitinib using ImageJ software.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

    VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis.

    J Biomol Screen, 2011,16: 141-154. Axitinib purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Axitinib purchased from Selleck.

    Axitinib treatment blocks VEGFR2 phosphorylation.

    HUVECs were starved O/N in EBM-2 basal medium with 1% FBS and antibiotic. Cells were pre-treated with Axitinib at 0.1, 1 and 10 nM concentrations. VEGF stimulation was 50 ng/ml for 10 minutes before cells were collected and protein isolated for immunoprecipitation with VEGFR2 followed by immunoblotting with VEGFR-2 and phospho-VEGFR-2.

     

     

    Dr. Cheri Pasch of UW Madison. Axitinib purchased from Selleck.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Biological Activity

Description Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.
Features Superior as second-line therapy relative to sorafenib (current standard-of-care).
Targets
VEGFR1/FLT1 [1]
(Porcine aorta endothelial cells)
VEGFR2/Flk1 [1]
(Porcine aorta endothelial cells)
VEGFR2/KDR [1]
(Porcine aorta endothelial cells)
VEGFR3 [1]
(Porcine aorta endothelial cells)
PDGFRβ [1]
(Porcine aorta endothelial cells)
0.1 nM 0.18 nM 0.2 nM 0.1 nM-0.3 nM 1.6 nM
In vitro

Axitinib could block the cellular autophosphorylation of VEGFR and VEGF-mediated endothelial cell viability, tube formation, and downstream signaling. Axitinib inhibits the proliferation of variable cell lines with IC50 of >10,000 nM (IGR-N91), 849 nM (IGR-NB8), 274 nM (SH-SY5Y) and 573 nM (non-VEGF stimulated HUVEC). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHOTWM2OD1yLkCwNFA2OTNizszN MmW3V2FPT0WU
NCI-H1703 NFXwRXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPXeWpRUUN3ME2wMlAxODlyMjFOwG0> M3T6UXNCVkeHUh?=
KASUMI-1 NGXFOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M136TGlEPTB;MD6wNFY5OiEQvF2= MXzTRW5ITVJ?
CGTH-W-1 NVT6UpZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP2TWM2OD1yLkCwO|IzKM7:TR?= Ml2xV2FPT0WU
A204 NUXifo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3w[WVIUUN3ME2wMlAxQTl{IN88US=> MXjTRW5ITVJ?
HOP-62 M2HkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfXZo43UUN3ME2wMlExQDN4IN88US=> MVLTRW5ITVJ?
H-EMC-SS NE\x[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrhS3Z6UUN3ME2wMlEyODB3IN88US=> MmXwV2FPT0WU
KU812 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS3PWhKSzVyPUCuNVY2PzdizszN M4f2[HNCVkeHUh?=
EM-2 M3H1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn6b2FKSzVyPUCuNVY5OTZizszN MXTTRW5ITVJ?
LAMA-84 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHOco1KSzVyPUCuNVc3PjVizszN M1ntW3NCVkeHUh?=
JAR M1rjdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLyOnJIUUN3ME2wMlI{QTh7IN88US=> MYXTRW5ITVJ?
G-361 NWPWfYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH2c5lKSzVyPUCuN|I{OjVizszN NI\PfI1USU6JRWK=
KG-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:5R2lEPTB;MD6zO|Y1OiEQvF2= M2PVTHNCVkeHUh?=
BV-173 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHznW|lKSzVyPUCuN|k{OiEQvF2= M2jMZ3NCVkeHUh?=
K5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwNEKxNlch|ryP M2XYTHNCVkeHUh?=
MEG-01 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf6VFJKSzVyPUCuOFI{PjFizszN M3XaXnNCVkeHUh?=
MFM-223 M3;RbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\nTWM2OD1yLkS0O|c3KM7:TR?= NH7TeHRUSU6JRWK=
BE-13 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXBSY5KSzVyPUCuOVExODhizszN M{f3TnNCVkeHUh?=
NEC8 MlLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXRUXBKSzVyPUCuO|IyOTNizszN NXTtOmN5W0GQR1XS
SW756 M4i0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3qPVJvUUN3ME2wMlk6QDR4IN88US=> MoSyV2FPT0WU
A2780 NVPVeW1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3NS3A3UUN3ME2xMlAyOTR4IN88US=> M4DaN3NCVkeHUh?=
NB14 NVrCOZhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HCcWlEPTB;MT6wNVgxOSEQvF2= M{PmenNCVkeHUh?=
H4 M2nob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnSTWM2OD1zLkC2OFIzKM7:TR?= NYrtRlVNW0GQR1XS
SK-OV-3 NX3zb3lFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHRUFFKSzVyPUGuNFY3OzNizszN NFLndllUSU6JRWK=
AN3-CA NX:xZotyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljmTWM2OD1zLkC4N|g6KM7:TR?= MlnpV2FPT0WU
A427 M3\2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLKTWM2OD1zLkGwN|gyKM7:TR?= M{jTR3NCVkeHUh?=
ES7 NFrEZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z5dGlEPTB;MT6xNVM{PCEQvF2= M1TseXNCVkeHUh?=
AGS NIO5V2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH63PFRKSzVyPUGuNVE{QTVizszN NUX1VGlKW0GQR1XS
G-402 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTFwMUS2PVQh|ryP MV7TRW5ITVJ?
ES5 NHSwXndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTFwMUeyOFgh|ryP MX3TRW5ITVJ?
DEL M1vmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\TdGlEPTB;MT6yOVQ2PyEQvF2= M1fyUnNCVkeHUh?=
NB10 MlrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXyZ5FFUUN3ME2xMlMzPTV5IN88US=> MXPTRW5ITVJ?
NCI-H1581 NFzSUZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXsTWM2OD1zLkO5NFQzKM7:TR?= MYTTRW5ITVJ?
D-566MG NVLxV4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTFwNEC2PFMh|ryP NVXvdnhyW0GQR1XS
LXF-289 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwNEO5PVYh|ryP MnnOV2FPT0WU
BT-549 NUPQU45VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvuWWdjUUN3ME2xMlU3QTB7IN88US=> M2\4eXNCVkeHUh?=
NKM-1 NInlVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwNkC1OVYh|ryP M{\CNXNCVkeHUh?=
SW780 M3rtSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTPO|RJUUN3ME2xMlY2OTV6IN88US=> MUPTRW5ITVJ?
NCI-H292 NXj2U|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwNk[zPFMh|ryP NUnSUZVIW0GQR1XS
HMV-II M3\UT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoKyTWM2OD1zLkewOFg5KM7:TR?= M3nnUHNCVkeHUh?=
ALL-PO NIPlNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LJb2lEPTB;MT64NFAyPSEQvF2= MWnTRW5ITVJ?
UACC-257 NUXUOHQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zXOGlEPTB;MT64NlE3OyEQvF2= MUnTRW5ITVJ?
PA-1 M3PnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoP5TWM2OD1zLkiyO|I2KM7:TR?= NU\iUJVZW0GQR1XS
HD-MY-Z M{DHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPieINKSzVyPUGuPFYzQDFizszN NELpNZFUSU6JRWK=
HSC-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvQVphKSzVyPUGuPVM5OzlizszN MYHTRW5ITVJ?
GCT NX;hRpd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTJwMEC5NVYh|ryP NIHlW|VUSU6JRWK=
RT-112 MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHV4FNUUN3ME2yMlE{PDJ2IN88US=> NVTtfIdmW0GQR1XS
A172 MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPKTWM2OD1{LkGzOlA3KM7:TR?= NWjJPHcyW0GQR1XS
HCE-T NE\WPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMkC1PVgh|ryP NUXTbGg{W0GQR1XS
YH-13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfaWlBFUUN3ME2yMlIyPjdzIN88US=> NXTDRY51W0GQR1XS
DK-MG M3noN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJwMkO4N|Qh|ryP NU\KdHFkW0GQR1XS
ACN NIn4dZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwMkO4O|Uh|ryP MknJV2FPT0WU
VA-ES-BJ M4rnSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTJwMkS5OVch|ryP NVnJWXpRW0GQR1XS
L-363 Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHuTWM2OD1{LkK4NFYyKM7:TR?= M4fkOnNCVkeHUh?=
HuH-7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jmTWlEPTB;Mj60NlE3PSEQvF2= NFXXd|ZUSU6JRWK=
A4-Fuk MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJwNEexOlgh|ryP MmrqV2FPT0WU
T-24 NHXxR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnYb4VQUUN3ME2yMlQ5ODN5IN88US=> Mmm5V2FPT0WU
GOTO MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;nWmlEPTB;Mj61N|AyOyEQvF2= MVfTRW5ITVJ?
MV-4-11 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJwNUmxOlkh|ryP MmDkV2FPT0WU
DMS-114 M3\5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu3TWM2OD1{Lk[2N|Q2KM7:TR?= NYTySGZxW0GQR1XS
MHH-NB-11 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzrRVJKSzVyPUKuO|AzQTlizszN MXLTRW5ITVJ?
CHP-212 NWKy[nJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInYOm5KSzVyPUKuPFIxQTFizszN NGHmVHNUSU6JRWK=
DMS-273 M1nRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwOUCyNFch|ryP MVvTRW5ITVJ?
SF295 M4mwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jFdWlEPTB;Mz6wNlU6PyEQvF2= MULTRW5ITVJ?
NCI-H1563 NX60eJNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW0TWM2OD1|LkG1NFA2KM7:TR?= NG\ncYxUSU6JRWK=
NCI-H446 MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULJPXl5UUN3ME2zMlIzQDB3IN88US=> NWTXNpF[W0GQR1XS
HCC1806 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPFWFNKSzVyPUOuNlc3PTdizszN M3zySnNCVkeHUh?=
SF126 MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jiOWlEPTB;Mz6zNFAyPyEQvF2= NH3vVFVUSU6JRWK=
SW982 NHuwTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNwM{O4O|Uh|ryP Mn3qV2FPT0WU
ES8 MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;lTWM2OD1|LkO0PVk6KM7:TR?= MoWwV2FPT0WU
SCC-4 M3zKUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjL[nZHUUN3ME2zMlUxOzl4IN88US=> M2LJRnNCVkeHUh?=
RPMI-8226 NYfx[|UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPXTWM2OD1|Lk[yOlE3KM7:TR?= MWnTRW5ITVJ?
EW-11 NYXiUoViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTNwNkOwNlIh|ryP NYHxdlZ[W0GQR1XS
COR-L105 NVriVFVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ryemlEPTB;Mz62N|M{PCEQvF2= M2fN[XNCVkeHUh?=
ES1 NVKxfnFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDDS4Z5UUN3ME2zMlg{ODl2IN88US=> NITUbm1USU6JRWK=
KMOE-2 NV7ESWhPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3MOI1KSzVyPUOuPVE5ODhizszN MmnKV2FPT0WU
ABC-1 NWnvfGZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC5O3Q1UUN3ME2zMlk{QTFzIN88US=> M4HkU3NCVkeHUh?=
NCI-H526 NHjIZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvyem1KSzVyPUOuPVkyOjZizszN MWXTRW5ITVJ?
HCC1395 NUnOWHNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTBNY4zUUN3ME2zMlk6PDh2IN88US=> NHP5fZlUSU6JRWK=
DU-145 M3Hjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPGR3htUUN3ME20MlEzQDJ3IN88US=> NFjPdYdUSU6JRWK=
JEG-3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLOW3RKSzVyPUSuNVU6OTZizszN NXHOfXJHW0GQR1XS
HCC1187 M3f5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTvWJZQUUN3ME20MlIyPTl5IN88US=> M2XMZnNCVkeHUh?=
LC-2-ad Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwMkKxO|ch|ryP NEnPR|RUSU6JRWK=
ONS-76 NVX0cHVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfRXHhKSzVyPUSuNlQyQTJizszN NYTHO2kzW0GQR1XS
CAL-27 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofDTWM2OD12LkK0N|Q1KM7:TR?= NWHFXJlnW0GQR1XS
8-MG-BA NVnLOGZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInkO2FKSzVyPUSuNlY3PThizszN MX7TRW5ITVJ?
HGC-27 NFjnbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPNTWM2OD12LkK5OlYh|ryP MnHwV2FPT0WU
Hs-578-T NX:3T2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjxTWM2OD12LkOxOFY5KM7:TR?= M{fLeXNCVkeHUh?=
EW-1 M4fKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\pNGlEPTB;ND61N|AyPCEQvF2= NV;DOIV5W0GQR1XS
SW1573 M2P0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTRwNUWxOlMh|ryP MXTTRW5ITVJ?
SNU-423 Ml\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3bHJOUUN3ME20MlYxPzlizszN NGroVoZUSU6JRWK=
HOS MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELnc4lKSzVyPUSuOlk4PyEQvF2= NUnnWYRsW0GQR1XS
LB1047-RCC MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{L5dmlEPTB;ND64NVQyQCEQvF2= Mon0V2FPT0WU
ChaGo-K-1 NXnuUol[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPaRVJKSzVyPUSuPFkxPDhizszN NFzMNYVUSU6JRWK=
A3-KAW MnL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTyTWM2OD12Lkm3N|UzKM7:TR?= NVT4cZB3W0GQR1XS
CAS-1 M3fMVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTRwOUm5NFgh|ryP MW\TRW5ITVJ?
NBsusSR MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO2XIN4UUN3ME21MlA{PTF2IN88US=> M1vLSnNCVkeHUh?=
KM12 NHX3dJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXxTWM2OD13LkK5PFI4KM7:TR?= MlPiV2FPT0WU
NCI-H1155 NVjvZoNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTVwM{ixPFUh|ryP NEHBSodUSU6JRWK=
EFM-19 NWXmVnJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GwbWlEPTB;NT60NVc{PyEQvF2= MWTTRW5ITVJ?
D-392MG NHTpSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XnVmlEPTB;NT61O|g1QSEQvF2= M2m3R3NCVkeHUh?=
JVM-3 M{\OU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfLO|hKSzVyPUWuO|I{OjVizszN NVOwXWtuW0GQR1XS
EW-16 NHnkOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonaTWM2OD13Lke1OVg{KM7:TR?= MVrTRW5ITVJ?
KARPAS-45 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPzTWdkUUN3ME21Mlg1OzJ3IN88US=> MYDTRW5ITVJ?
NCI-H28 NIH1TFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSwTWM2OD13Lki3PVE5KM7:TR?= Mlr5V2FPT0WU
COLO-829 NVLkdGhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGNI5KSzVyPUWuPVE2ODRizszN Mk[zV2FPT0WU
KM-H2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnKZnBSUUN3ME21MlkzOzl3IN88US=> NHfyb|FUSU6JRWK=
NCI-H82 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHi[YZ{UUN3ME21MlkzPzdzIN88US=> NHvScolUSU6JRWK=
OAW-42 NUHwfVZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXrTWM2OD13Lkm4PFIyKM7:TR?= MnfXV2FPT0WU
A704 M2[0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDJOJVJUUN3ME22MlExPTd2IN88US=> MnLqV2FPT0WU
NCI-H1048 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrvVYZGUUN3ME22MlExPTl7IN88US=> NGnRV|FUSU6JRWK=
LOXIMVI Mm\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnWZphKSzVyPU[uNVEzPDhizszN Mki1V2FPT0WU
MKN45 M{XRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWG4Z4l4UUN3ME22MlI3ODF4IN88US=> M1zwU3NCVkeHUh?=
D-502MG Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHLO3RKSzVyPU[uNlg5PTdizszN NV3ZS2dWW0GQR1XS
HUTU-80 NWDLdWtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XiPGlEPTB;Nj60NVY5QCEQvF2= NHfOOFZUSU6JRWK=
S-117 M3K4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfDTWM2OD14LkWwNlY4KM7:TR?= NV;jVGViW0GQR1XS
HCC1569 MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HqR2lEPTB;Nj61N|c{PyEQvF2= NYW3SW15W0GQR1XS
J-RT3-T3-5 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXvW5FyUUN3ME22MlU1PTd{IN88US=> NVLwSoppW0GQR1XS
OC-314 NIP6eVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPVbZVKSzVyPU[uPVEyPTlizszN NVPyV25pW0GQR1XS
SNU-449 NGHkfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjqN4xKSzVyPUeuNFExPzJizszN MVPTRW5ITVJ?
NCI-H720 M4HaU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nCcmlEPTB;Nz6xPVM1PSEQvF2= M2GySXNCVkeHUh?=
KP-N-YS MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjUbZZKSzVyPUeuNlA4OiEQvF2= M{TEOHNCVkeHUh?=
IGROV-1 M1TBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPUTWM2OD15LkOyN|g3KM7:TR?= MVPTRW5ITVJ?
SK-PN-DW M3jOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fuNGlEPTB;Nz60PFE2KM7:TR?= MlvzV2FPT0WU
HCC1419 NWm0UVBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTGTWM2OD15LkWzJO69VQ>? NGnLPFdUSU6JRWK=
HAL-01 M4mwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i4NGlEPTB;Nz62NFY1PCEQvF2= NE\W[lBUSU6JRWK=
HCC2998 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkThTWM2OD15Lk[wO|Q{KM7:TR?= NVXROmpuW0GQR1XS
SK-N-FI MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;WdYlKSzVyPUeuOlMxOzNizszN NEj4RnFUSU6JRWK=
GI-ME-N NWjTS5N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e3RmlEPTB;Nz62OFk{PCEQvF2= Mn\1V2FPT0WU
SW1088 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTdwNkW4NlYh|ryP Mn\wV2FPT0WU
IA-LM M2HiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXXe3pjUUN3ME23MlY5PjF|IN88US=> MYjTRW5ITVJ?
SK-NEP-1 M1X5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjPNmtKSzVyPUeuOlk3OSEQvF2= M{CwenNCVkeHUh?=
MDA-MB-415 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3m5T2lEPTB;Nz64PVE5PiEQvF2= M{XCeHNCVkeHUh?=
COLO-800 M1\BUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDKTWM2OD15Lkm0OFkzKM7:TR?= NVjkdXMyW0GQR1XS
NCI-H2228 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwMUW3PFMh|ryP M2n1V3NCVkeHUh?=
D-423MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf2TWM2OD16LkKxO|Ih|ryP NH\Vdo9USU6JRWK=
TE-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrRSGdKSzVyPUiuOFQ{OTZizszN M1LSV3NCVkeHUh?=
NOS-1 MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTwTWM2OD16LkWxOVM1KM7:TR?= NF3PTmlUSU6JRWK=
8505C NFLrbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRThwNkS4NlQh|ryP Mn;ZV2FPT0WU
HEC-1 NYjyUJhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfsWXJKSzVyPUiuO|g1OzlizszN MVHTRW5ITVJ?
TE-11 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7GTWM2OD16Lkm5OVUyKM7:TR?= MXvTRW5ITVJ?
CTB-1 M3PuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTlwMEG0N|Mh|ryP NEPpUHdUSU6JRWK=
TGBC11TKB NUTEOW9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrsTWM2OD17LkCyNlQyKM7:TR?= MnXuV2FPT0WU
NB17 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTlwMUi4O{DPxE1? M17MfHNCVkeHUh?=
Becker MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDBdIlKSzVyPUmuOFE6PDRizszN MXfTRW5ITVJ?
SN12C MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXWTWM2OD17LkS1NlM1KM7:TR?= NELGeopUSU6JRWK=
COLO-320-HSR MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLSTWM2OD17Lk[wNlM4KM7:TR?= Ml[0V2FPT0WU
D-283MED M4HZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf6eJVoUUN3ME25MlY{ODd{IN88US=> MlzQV2FPT0WU
D-263MG NXXMdVNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlwOEOzPFQh|ryP MnLlV2FPT0WU
MEL-JUSO NIX5[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fkXGlEPTB;OT65NFEzPyEQvF2= MorpV2FPT0WU
T98G MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfac213UUN3ME25MlkxOjB|IN88US=> M33zVHNCVkeHUh?=
HLE NELuXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCyU2JKSzVyPUmuPVA6ODlizszN M{TyVXNCVkeHUh?=
Ca9-22 MoPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHaVFZKSzVyPUGwMlA3PjVizszN NY\Ue|N1W0GQR1XS
OS-RC-2 NGroeHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnzTWM2OD1zMD6xNFQ2KM7:TR?= NIfjRodUSU6JRWK=
T47D MofvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXPTWM2OD1zMD6xOVUh|ryP NVXaeWplW0GQR1XS
GI-1 M3n1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq5XI5NUUN3ME2xNE4{PTN|IN88US=> MlTVV2FPT0WU
NUGC-3 MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFyLkS0NFIh|ryP M4rIenNCVkeHUh?=
MDA-MB-361 NU\3blJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HEemlEPTB;MUCuOFQ{OiEQvF2= NYXCSnJbW0GQR1XS
SCC-15 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP4TWM2OD1zMD60O|E5KM7:TR?= NHvsWndUSU6JRWK=
KS-1 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXuVmFTUUN3ME2xNE43OzBzIN88US=> M3vrfnNCVkeHUh?=
CAL-12T NELa[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXRfpZRUUN3ME2xNE43OzZzIN88US=> NELkW5NUSU6JRWK=
OVCAR-4 NUHmTpRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\5TJFXUUN3ME2xNE44ODZ6IN88US=> M1\yPHNCVkeHUh?=
HuP-T4 NVraTXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFzLkCzNlgh|ryP MknGV2FPT0WU
NCI-H358 M3TiWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXqTWM2OD1zMT6yOlU4KM7:TR?= M4LtXXNCVkeHUh?=
HO-1-N-1 M2LPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXDTWM2OD1zMT6zN|k5KM7:TR?= MmjlV2FPT0WU
NH-12 NGiyTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HlXWlEPTB;MUGuOVM4QCEQvF2= NXHsRZRRW0GQR1XS
MOLT-4 NGPwWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzLkW5PFUh|ryP NEnCTmtUSU6JRWK=
K-562 M{HSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TxR2lEPTB;MUGuO|I1QCEQvF2= M3HXbnNCVkeHUh?=
ES6 M2XxV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3TTWM2OD1zMT64OVgyKM7:TR?= NF3oSZdUSU6JRWK=
RO82-W-1 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTQTWM2OD1zMT65NFY1KM7:TR?= NUmyV5VjW0GQR1XS
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\O[oVEUUN3ME2xNU46OzJizszN NHvwcppUSU6JRWK=
23132-87 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfETWM2OD1zMj6wPFIyKM7:TR?= MnzxV2FPT0WU
A549 M4rvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXHTWM2OD1zMj6zNlg2KM7:TR?= NEXpbIZUSU6JRWK=
NCI-H23 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorBTWM2OD1zMj61NFI3KM7:TR?= M3q0SHNCVkeHUh?=
H9 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBSVI2UUN3ME2xNk42PTd5IN88US=> M2fHV3NCVkeHUh?=
LB771-HNC M{TjdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nJ[2lEPTB;MUKuO|Y2KM7:TR?= NIfNRZhUSU6JRWK=
QIMR-WIL NVLReZU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzzTWM2OD1zMj64NlU5KM7:TR?= NGL4UI9USU6JRWK=
HSC-3 NVHhRmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHaVlFKSzVyPUGyMlkzPzZizszN NVrEd|VHW0GQR1XS
PFSK-1 M33oUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4T4SGlEPTB;MUKuPVUxPyEQvF2= MUjTRW5ITVJ?
ETK-1 NHX4WmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrDcHlbUUN3ME2xN{4xPzd7IN88US=> NUSybW8{W0GQR1XS
SW1710 MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF|LkO2OFEh|ryP NG\PUplUSU6JRWK=
COLO-684 M{e1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF|LkS1OFEh|ryP MWnTRW5ITVJ?
RPMI-7951 MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\GTWM2OD1zMz61NVM3KM7:TR?= NEPFRYdUSU6JRWK=
A101D NHjTfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PnVGlEPTB;MUOuOVM1QSEQvF2= M4HQU3NCVkeHUh?=
KE-37 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D0b2lEPTB;MUOuOVg5PyEQvF2= MkS0V2FPT0WU
SiHa MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\xR2lEPTB;MUOuPFM1PiEQvF2= MWPTRW5ITVJ?
NCI-H226 M2fMNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHPVINUUUN3ME2xN{45QDB6IN88US=> MlrwV2FPT0WU
DB NE\tUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnxZ3lKSzVyPUGzMlk6OjhizszN M{n4Z3NCVkeHUh?=
HT-1197 NYLLUVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF2LkC4NFkh|ryP MVrTRW5ITVJ?
SBC-5 NXTRfm4zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jhU2lEPTB;MUSuNVM3OiEQvF2= M4P4e3NCVkeHUh?=
VMRC-RCZ NXjW[49oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u3[2lEPTB;MUSuOVc4PCEQvF2= MkXCV2FPT0WU
697 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zL[WlEPTB;MUSuOlI4KM7:TR?= Mm\JV2FPT0WU
OMC-1 M3PxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTF2Lke4PFgh|ryP NFfSWndUSU6JRWK=
SKG-IIIa NYLaO3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF2LkiwNFEh|ryP MVjTRW5ITVJ?
DOK MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW5U2pKSzVyPUG0Mlk6OzNizszN M3zo[nNCVkeHUh?=
NCI-H2029 NUP6XHF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfa[npPUUN3ME2xOU4{PjB{IN88US=> M1;PUHNCVkeHUh?=
NCI-H2009 NEXHdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPidItKSzVyPUG1MlUxQTVizszN M3TkZ3NCVkeHUh?=
LK-2 M3fCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X6c2lEPTB;MUWuOlQ1QSEQvF2= NFfKU|NUSU6JRWK=
NCI-H661 NFLKOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonJTWM2OD1zNT65NFc2KM7:TR?= NX;tc4pjW0GQR1XS
GT3TKB MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLHTWM2OD1zNj6wOlc3KM7:TR?= M{jvfXNCVkeHUh?=
GP5d NWfEdIVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\5[nlKSzVyPUG2MlM1OiEQvF2= NFH5eIJUSU6JRWK=
SK-MEL-2 M3TFXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF4LkS0PFUh|ryP MXTTRW5ITVJ?
SK-UT-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Z[VNSUUN3ME2xOk42PjVizszN NYL3XlVKW0GQR1XS
NB7 NF\rU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF4Lk[5O|Eh|ryP NVrxR20xW0GQR1XS
NCI-H460 NXXCdYl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF4LkezNlYh|ryP MVPTRW5ITVJ?
8305C Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK1TWM2OD1zNj63PFc4KM7:TR?= M2fveXNCVkeHUh?=
CaR-1 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXkTWM2OD1zNj64NVEyKM7:TR?= MlLxV2FPT0WU
D-247MG Ml7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkP6TWM2OD1zNj64OlI2KM7:TR?= MXHTRW5ITVJ?
LoVo MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Dd4ZGUUN3ME2xOk46PDh6IN88US=> MV7TRW5ITVJ?
NCI-H2405 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe1[VdKSzVyPUG3MlE6ODhizszN MX3TRW5ITVJ?
AU565 NX3ZNZQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nvSWlEPTB;MUeuNlI2KM7:TR?= NGnvdIVUSU6JRWK=
OCI-AML2 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX3TWM2OD1zNz61N|E4KM7:TR?= MUDTRW5ITVJ?
22RV1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq5S4IyUUN3ME2xO{42QDh2IN88US=> M4H1d3NCVkeHUh?=
HT-144 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonzTWM2OD1zNz62OVk5KM7:TR?= NH;HXYhUSU6JRWK=
HuO9 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXHUldKSzVyPUG3MlcxOzFizszN M{\uPHNCVkeHUh?=
Daoy M{i3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLSTWM2OD1zNz63NVg1KM7:TR?= MX;TRW5ITVJ?
SJRH30 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;RS5B[UUN3ME2xO{45PDh7IN88US=> Mn3yV2FPT0WU
CHL-1 NWHWVWNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml74TWM2OD1zNz65NlQ6KM7:TR?= NYLJUI9zW0GQR1XS
J82 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M120SmlEPTB;MUeuPVY{PSEQvF2= M33URXNCVkeHUh?=
COR-L23 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ITWM2OD1zOD6wNFEyKM7:TR?= M2TFcHNCVkeHUh?=
SNU-C2B M3zFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHNTWM2OD1zOD6yNlc3KM7:TR?= M{j3PXNCVkeHUh?=
NCI-H1770 NGT5clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX76UHlIUUN3ME2xPE41PjF3IN88US=> NH75[4RUSU6JRWK=
MHH-PREB-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjaT4Y1UUN3ME2xPE42Pjl5IN88US=> NXexSXZnW0GQR1XS
ES3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfJToJKSzVyPUG4MlU5QDNizszN Mm\GV2FPT0WU
MDA-MB-231 Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTF6Lk[1NFIh|ryP MkfHV2FPT0WU
MN-60 M4jnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7U[FFKSzVyPUG5MlA2QTJizszN M3XuV3NCVkeHUh?=
EPLC-272H NH7RVplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEeybXVKSzVyPUG5MlM4ODhizszN NGjsU3RUSU6JRWK=
SW948 NIG5bmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF7LkO5N|Qh|ryP NEnkR2FUSU6JRWK=
MOLT-13 NH\5PJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXlPJhKSzVyPUG5MlQ2PDZizszN NYTTZWxKW0GQR1XS
HL-60 M4nvSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJyLkKxOFEh|ryP M3H1WHNCVkeHUh?=
CP50-MEL-B NYHqO2N5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3izb2lEPTB;MkCuOFc1QCEQvF2= M17rOnNCVkeHUh?=
NTERA-S-cl-D1 M4q1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjvRZdSUUN3ME2yNE41QTd6IN88US=> NX3BcJRIW0GQR1XS
KINGS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfoU|VoUUN3ME2yNE44QTZ5IN88US=> NUnpS41vW0GQR1XS
DOHH-2 M3jFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOZ2lEPTB;MkCuPVA3KM7:TR?= NEPrPJBUSU6JRWK=
BB65-RCC NYfHOlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyWoZWUUN3ME2yNE46Ojh3IN88US=> NXHNfmlzW0GQR1XS
NB12 NFfoVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJzLkCzPVQh|ryP MoHtV2FPT0WU
KY821 Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJzLkW4NkDPxE1? NV;PNHNyW0GQR1XS
PSN1 NVjVcY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\jTWM2OD1{MT62OFU{KM7:TR?= MW\TRW5ITVJ?
EGI-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G3PGlEPTB;MkGuO|Q2PCEQvF2= Ml;CV2FPT0WU
CTV-1 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGwdHNUUUN3ME2yNk4{ODNzIN88US=> M1XqfHNCVkeHUh?=
TI-73 M33TWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXsUZNKSzVyPUKyMlM1QThizszN MYHTRW5ITVJ?
LCLC-103H MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjoVXRKSzVyPUKyMlQ4PTJizszN NWjXbmF3W0GQR1XS
D-542MG M{XOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DsOGlEPTB;MkKuOVU2QCEQvF2= MV;TRW5ITVJ?
ATN-1 NEfXRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHTSpBKSzVyPUKyMlY1OzlizszN NXfvO|V2W0GQR1XS
SK-MEL-1 M{ToV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ{LkizOlgh|ryP M1\wPHNCVkeHUh?=
HDLM-2 NY\BNXN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETXcVZKSzVyPUKzMlE1PzhizszN MY\TRW5ITVJ?
UM-UC-3 MnTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ|LkG5OFQh|ryP NF\YdpVUSU6JRWK=
NCI-H1573 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1{Mz60OlgyKM7:TR?= MWjTRW5ITVJ?
NCI-H520 M1rIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfJfmRCUUN3ME2yN{41QTR6IN88US=> MYXTRW5ITVJ?
ESS-1 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXGemNKSzVyPUKzMlgxPTlizszN Mm\YV2FPT0WU
COR-L88 M3jpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;Le4drUUN3ME2yN{46PDd3IN88US=> M1vhNXNCVkeHUh?=
TGBC24TKB MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfYTWM2OD1{ND6wN|EzKM7:TR?= NYjwNnRRW0GQR1XS
HCC1937 NEfvOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;YR3lYUUN3ME2yOE4yKM7:TR?= MlTCV2FPT0WU
RS4-11 NXv4ZnprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTJ2LkG0NkDPxE1? NFHhUFRUSU6JRWK=
HCC38 MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3m1c2lEPTB;MkSuNlM6PCEQvF2= NXTSOHBLW0GQR1XS
RPMI-2650 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ2Lk[xOlIh|ryP M4THRXNCVkeHUh?=
P12-ICHIKAWA MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoG4TWM2OD1{ND62NlU5KM7:TR?= NIiwd29USU6JRWK=
YAPC M{HYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD2VIpKSzVyPUK0MlgzOTRizszN NXHBVmVMW0GQR1XS
NB13 NI\C[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\XTWM2OD1{NT6yOlEyKM7:TR?= M4rwT3NCVkeHUh?=
SK-N-AS M3jVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jMW2lEPTB;MkWuPFU5PCEQvF2= NVHPcnpLW0GQR1XS
SK-N-DZ NX7LWJBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJ4LkC0PUDPxE1? MonlV2FPT0WU
LS-411N M2DRe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHJSpRKSzVyPUK2MlIxOzhizszN MXLTRW5ITVJ?
NCI-H810 M2m4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJ4LkOxNVIh|ryP M2LUNXNCVkeHUh?=
NCI-SNU-1 NUPPfWJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\rTWM2OD1{Nj61OFU1KM7:TR?= MXPTRW5ITVJ?
HH MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1n6VmlEPTB;Mk[uOVUzQSEQvF2= MlfmV2FPT0WU
U-2-OS NVLyNpkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLYbnhKSzVyPUK2Mlc{QDJizszN MojxV2FPT0WU
SF539 MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmraTWM2OD1{Nj64NFE5KM7:TR?= MmLPV2FPT0WU
NCI-H2052 M{H6dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tt[WlEPTB;MkeuNFg3KM7:TR?= NWix[W1PW0GQR1XS
A673 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJ5LkKxNFIh|ryP NGfWOnhUSU6JRWK=
WM-115 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzSR3FKSzVyPUK3Mlc4PjdizszN M37ZXnNCVkeHUh?=
SW48 NI\Sb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqbFNkUUN3ME2yO{45ODB3IN88US=> MoT4V2FPT0WU
NOMO-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHjOoZzUUN3ME2yO{45PTN{IN88US=> NULkb5ZMW0GQR1XS
PC-3 NHfEclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ5Lki5OFEh|ryP MVTTRW5ITVJ?
UMC-11 M2rsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJ5LkmzOFMh|ryP MUfTRW5ITVJ?
U-118-MG NIexU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD1{OD6wNVI{KM7:TR?= NYDHSW84W0GQR1XS
NCI-H2452 NVH5O41vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHKUJBsUUN3ME2yPE4xQDJ{IN88US=> M{m3SXNCVkeHUh?=
CAMA-1 M3q3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDhXWVTUUN3ME2yPE45PTZ2IN88US=> NFWz[GdUSU6JRWK=
MC-IXC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1flbWlEPTB;MkmuNlM3PiEQvF2= NULhboJjW0GQR1XS
ES4 NUfjUplQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYm5eVRwUUN3ME2yPU4{OTd{IN88US=> NFr0S3dUSU6JRWK=
BHT-101 NVvtPGFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTnRmZKSzVyPUK5MlMzOSEQvF2= NFfiSWhUSU6JRWK=
KP-4 NVTzSGI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTvVmNKSzVyPUK5MlUyPiEQvF2= M2r1[3NCVkeHUh?=
CAL-54 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPEU25QUUN3ME2yPU42PDR3IN88US=> NYfESGkzW0GQR1XS
5637 NYfreVJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr5UnhKSzVyPUK5MlY1OjFizszN MnTXV2FPT0WU
MOLT-16 MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjnW|J7UUN3ME2yPU44OjZ7IN88US=> NVT5bXBiW0GQR1XS
Ca-Ski M3\jfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPlOGFKSzVyPUK5Mlk1PiEQvF2= NIGyOlZUSU6JRWK=
AsPC-1 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTNyLkCyNVIh|ryP NGPCc5dUSU6JRWK=
MSTO-211H NVSye5o6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNyLkG1JO69VQ>? NEPzfnZUSU6JRWK=
L-428 NWTrTZp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu3TWM2OD1|MD60NFUh|ryP NWnqSXlIW0GQR1XS
SW1463 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTNyLkWzPFMh|ryP NGnlUXlUSU6JRWK=
NCI-H1648 NWD5ZpdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LpZ2lEPTB;M{CuOVU4PCEQvF2= MVTTRW5ITVJ?
CAKI-1 NGe4dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4njNGlEPTB;M{CuO|cxOiEQvF2= MYDTRW5ITVJ?
YKG-1 MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTNzLkCyOlMh|ryP M4[1[HNCVkeHUh?=
A2058 M3fCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPUTWM2OD1|MT6xNVY1KM7:TR?= NHuwfoZUSU6JRWK=
A375 M1nNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\WVXY2UUN3ME2zNU4yPjl4IN88US=> MoH5V2FPT0WU
SNB75 M3eySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfK[HJMUUN3ME2zNU4zPDN3IN88US=> MlXhV2FPT0WU
SK-HEP-1 M1;Ucmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;nV5FKSzVyPUOxMlQzPzFizszN NV;yOJVFW0GQR1XS
ME-180 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILZTYFKSzVyPUOxMlY2PDJizszN M1G4RXNCVkeHUh?=
NCI-H209 M{P5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\4S2V[UUN3ME2zNU45OjR5IN88US=> MVLTRW5ITVJ?
HC-1 NHrjepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN{LkG0OFYh|ryP NX20boxNW0GQR1XS
LB373-MEL-D M4PWNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLtWJRWUUN3ME2zNk4yQTdzIN88US=> NYj4OY9iW0GQR1XS
SNU-387 NUHkdFZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN{LkOxPVEh|ryP M3LXdnNCVkeHUh?=
C32 NFjoVm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rPd2lEPTB;M{KuN|M2OyEQvF2= NIq5TotUSU6JRWK=
EW-13 Ml2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnMTWM2OD1|Mj65OFA5KM7:TR?= MX\TRW5ITVJ?
BFTC-905 MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTN|LkWxN|Yh|ryP M3LLVHNCVkeHUh?=
NCI-H1299 NFq0UFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jKRmlEPTB;M{OuOVYzOSEQvF2= NYjsSohsW0GQR1XS
LU-135 NUHvOWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTN|LkiwNUDPxE1? M4nUTnNCVkeHUh?=
NCI-H2122 NVzXNlV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37GbGlEPTB;M{OuPVk3PiEQvF2= NYnYboYyW0GQR1XS
SK-LMS-1 M1LRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HTS2lEPTB;M{SuOFExPyEQvF2= MoCzV2FPT0WU
LNCaP-Clone-FGC NVTzWI9mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\TXoFKSzVyPUO0Mlg2OTVizszN NIH0dFdUSU6JRWK=
NCI-H1092 NFrs[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7qbHNuUUN3ME2zOU4zPzR5IN88US=> NFz4UFJUSU6JRWK=
MS-1 M{S5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULwTmJyUUN3ME2zOU4{ODN6IN88US=> MUXTRW5ITVJ?
KYSE-510 NUf4[WpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXBdXBKSzVyPUO1MlUxPDJizszN MUTTRW5ITVJ?
NCI-H1793 NEHRRZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\TO4FKSzVyPUO1MlY2PDVizszN M{fMOnNCVkeHUh?=
MIA-PaCa-2 NIizdnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN4LkC0PVYh|ryP MX\TRW5ITVJ?
EW-22 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\oepJKSzVyPUO2MlQxPzJizszN NIPFeWxUSU6JRWK=
IGR-1 NIPpfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDIPFRKSzVyPUO2MlgyQDRizszN MoL1V2FPT0WU
HT-1080 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG5dnRKSzVyPUO3MlEzPSEQvF2= M3;jVXNCVkeHUh?=
M14 NGTWWGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;pTWM2OD1|Nz6xOlQzKM7:TR?= M1\ic3NCVkeHUh?=
786-0 NWT0WIdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\USWlEPTB;M{euNlc6PCEQvF2= NF6xPYFUSU6JRWK=
MZ2-MEL M37tbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly2TWM2OD1|Nz60OVAyKM7:TR?= NV;TZmJoW0GQR1XS
NCI-H510A M2rRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPoOINKSzVyPUO3Mlk1OTJizszN MYXTRW5ITVJ?
LAN-6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\je|JiUUN3ME2zO{46PTh{IN88US=> MkHvV2FPT0WU
SW620 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTN6LkS5O|Qh|ryP M4jmenNCVkeHUh?=
LB2241-RCC M1vKXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPyfGlKSzVyPUO5MlgzODVizszN NVnCWVlkW0GQR1XS
Detroit562 NW\5[IVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLyUWJKSzVyPUSwMlEzPjhizszN M3vDeXNCVkeHUh?=
HN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPCTWM2OD12MD6xO|gzKM7:TR?= NVSyPVdDW0GQR1XS
HCT-15 NGf4boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnGc3RKSzVyPUSwMlU6ODdizszN NVj6OWFiW0GQR1XS
C2BBe1 NEm4SGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfxT4RtUUN3ME20NE46OTV5IN88US=> NHOxUHJUSU6JRWK=
A498 NEnlfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG0RZRXUUN3ME20NU4{ODF3IN88US=> MVXTRW5ITVJ?
SK-MEL-24 M4H6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkTWM2OD12MT60O|I2KM7:TR?= MmGyV2FPT0WU
OVCAR-5 M3r2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRzLke3Olch|ryP NGS0co9USU6JRWK=
NCI-H1792 NFTtO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYC0RXlnUUN3ME20NU46QDJzIN88US=> NGr5SopUSU6JRWK=
KOSC-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXBTWM2OD12Mj6yOlk6KM7:TR?= MUfTRW5ITVJ?
Mo-T Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTtd|NKSzVyPUSyMlg6PThizszN NGLlcY1USU6JRWK=
CFPAC-1 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR|LkS5OFQh|ryP NGX2PItUSU6JRWK=
CAL-51 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnUTWM2OD12Mz61OlA2KM7:TR?= MXXTRW5ITVJ?
RH-18 NF3aS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PGSWlEPTB;NEOuPFA2KM7:TR?= NUHW[3hiW0GQR1XS
EC-GI-10 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR|LkizOFch|ryP M{HjenNCVkeHUh?=
HSC-2 Ml21S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5SI5KSzVyPUS0MlAxQSEQvF2= NGHpToFUSU6JRWK=
ML-2 NYXxZ3NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLsbGlDUUN3ME20OU4zPjJzIN88US=> NI\lWJdUSU6JRWK=
KNS-81-FD MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HPcWlEPTB;NEWuO|M3PSEQvF2= NFLEfHVUSU6JRWK=
NB6 M4LyWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD12Nj6xNVEh|ryP MYrTRW5ITVJ?
MCF7 NIG0TpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q0UGlEPTB;NE[uOVU{OyEQvF2= MlrNV2FPT0WU
P30-OHK MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C5OWlEPTB;NE[uPFEyPyEQvF2= M1fhXXNCVkeHUh?=
BPH-1 NGH0O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfuU5lQUUN3ME20Ok46QDB3IN88US=> M4HhO3NCVkeHUh?=
U251 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfOdW9lUUN3ME20Ok46QTRizszN NILrNYVUSU6JRWK=
MKN1 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rYUmlEPTB;NEeuOVE{PyEQvF2= NHXSTFJUSU6JRWK=
A431 NVfhT4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzTWM2OD12Nz64N|M5KM7:TR?= NVrZfYIxW0GQR1XS
C8166 NYPwbYU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR7LkKwN|kh|ryP NF7jb3FUSU6JRWK=
HEL NYnQZnp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\zO2lEPTB;NEmuOFA3PCEQvF2= NEfLcZdUSU6JRWK=
RMG-I NXyyXVhlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTR7LkS0OFQh|ryP MYXTRW5ITVJ?
CAL-72 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojMTWM2OD12OT62NFc2KM7:TR?= NFz4UGdUSU6JRWK=
SW962 NHzNSFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3ZWnl[UUN3ME20PU46OzN{IN88US=> MWfTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Axitinib exhibits primary inhibition to orthotopically transplanted models such as M24met (melanoma), HCT-116 (colorectal cancer), and SN12C (renal cell carcinoma). [1] Axitinib delays the tumor growth with 11.4 days compared to the controls (p.o. 30 mg/kg) and decreases the Mean Vessels Density (MVD) to 21, compared to 49 in controls, in IGR-N91 flank xenografts. [2] Axitinib significantly inhibits growth and disrupts tumor microvasculature in BT474 breast cancer model at 10-100 mg/kg. [3] Axitinib has shown single-agent activity in variable tumors, including renal cell carcinoma, thyroid cancer, non-small cell lung cancer, and melanoma.

Protocol

Kinase Assay:

[1]

+ Expand

Cellular receptor kinase phosphorylation assay:

Porcine aorta endothelial (PAE) cells, which overexpress full-length VEGFR2, PDGFRβ, Kit, and NIH-3T3, which overexpress murine VEGFR2 (Flk-1) or PDGFRα, are generated. The 96-well plates are coated with 100 μL/well of 2.5 μg/mL anti-VEGFR2 antibody, 0.75 μg/mL anti-PDGFRβ antibody, 0.25 μg/mL anti-PDGFRα antibody, 0.5 μg/mL anti-KIT antibody, or 1.20 μg/mL anti-Flk-1 antibody to prepare ELISA capture plates. Then phosphorylation of RTK is measured by ELISA.
Cell Research:

[2]

+ Expand
  • Cell lines: HUVEC, SH-SY5Y, IGR-N91 and IGR-NB8 cells
  • Concentrations: 1 nM - 10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are seeded in a 96-well plate at a density of 5 × 104 and cultured for 24 hours. Axitinib is added to the cells at concentrations ranging from 1 nM to 10 μM. Cell viability is measured after 72 hours by MTS tetrazolium substrate and IC50 values are calculated.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: BT474 breast cancer cells are implanted subcutaneously into Immune-deficient female mice (Nu/nu; age 8-12 weeks).
  • Formulation: 0.5% carboxymethylcellulose (CMC)
  • Dosages: 10, 30 or 100 mg/kg
  • Administration: Oral daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 35 mg/mL warmed (90.56 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
0.5% CMC
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 386.47
Formula

C22H18N4OS

CAS No. 319460-85-0
Storage powder
in solvent
Synonyms AG 013736

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02156895 Not yet recruiting Advanced Renal Cell Carcinoma Pfizer June 2017 --
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer September 2016 Phase 1|Phase 2
NCT02859012 Recruiting Recurrent ACC, metastaticACC, Unreaectable ACC Seoul National University Hospital September 2016 Phase 2
NCT02853331 Recruiting Renal Cell Carcinoma Merck Sharp & Dohme Corp. September 2016 Phase 3
NCT02762513 Recruiting Squamous Cell Carcinoma of the Head and Neck University of Michigan Cancer Center|National Comprehensive Cancer Network August 2016 Phase 2
NCT02684006 Recruiting Renal Cell Cancer Pfizer March 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Axitinib | Axitinib supplier | purchase Axitinib | Axitinib cost | Axitinib manufacturer | order Axitinib | Axitinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID